Antoine Hollebecque

Dr. Antoine Hollebecque

Gustave Roussy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Hepatology
Verified
Journal Article
Closed access
PDF file
ALAlexandre Louvet
Alexandre Louvet
SNSylvie Naveau
Sylvie Naveau
MAMarcelle Abdelnour
Marcelle Abdelnour
MRMarie-José Ramond
Marie-José Ramond
EDEmmanuel Diaz
Emmanuel Diaz
PMPhilippe Mathurin
Philippe Mathurin

1 April 2018 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RCRyan B. Corcoran
Ryan B. Corcoran
TAThierry André
Thierry André
CAChloe E. Atreya
Chloe E. Atreya
JSJan H.M. Schellens
Jan H.M. Schellens
TYTakayuki Yoshino
Takayuki Yoshino
ECEric Van Cutsem
Eric Van Cutsem
Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that the lack of efficacy in BRAFV600E colorectal cancer is due to adaptive feedback reactivation of MAPK signaling, often mediated by EGFR. This clinical trial evaluated BRAF and EGFR inhibition with dabrafenib (D) + panitumumab (P) ± MEK inhibition with trametinib (T) to achieve greater MAPK suppression and improved efficacy in 142 patients with BRAFV600E colorectal cancer. Confirmed response rates for D+P, D+T+P, and T+P were 10%, 21%, and 0%, respectively. Pharmacodynamic analysis of paired pretreatment and on-treatment biopsies found that efficacy of D+T+P correlated with increased MAPK suppression. Serial cell-free DNA analysis revealed additional correlates of response and emergence of KRAS and NRAS mutations on disease progression. Thus, targeting adaptive feedback pathways in BRAFV600E colorectal cancer can improve efficacy, but MAPK reactivation remains an important primary and acquired resistance mechanism. Significance: This trial demonstrates that combined BRAF + EGFR + MEK inhibition is tolerable, with promising activity in patients with BRAFV600E colorectal cancer. Our findings highlight the MAPK pathway as a critical target in BRAFV600E colorectal cancer and the need to optimize strategies inhibiting this pathway to overcome both primary and acquired resistance. Cancer Discov; 8(4); 428–43. ©2018 AACR. See related commentary by Janku, p. 389. See related article by Hazar-Rethinam et al., p. 417. This article is highlighted in the In This Issue feature, p. 371

1 August 2009 in Gastroenterology
Verified
Journal Article
Closed access
PMPhilippe Mathurin
Philippe Mathurin
AHAntoine Hollebecque
Antoine Hollebecque
LALaurent Arnalsteen
Laurent Arnalsteen
DBDavid Buob
David Buob
ELEmmanuelle Leteurtre
Emmanuelle Leteurtre
FPFrançois Pattou
François Pattou

1 August 2009 in Gastroenterology
Verified
Journal Article
Closed access
ALAlexandre Louvet
Alexandre Louvet
FWFaustine Wartel
Faustine Wartel
HCHélène Castel
Hélène Castel
SDSébastien Dharancy
Sébastien Dharancy
AHAntoine Hollebecque
Antoine Hollebecque
PMPhilippe Mathurin
Philippe Mathurin

1 February 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ISIan M. Silverman
Ian M. Silverman
AHAntoine Hollebecque
Antoine Hollebecque
LFLuc Friboulet
Luc Friboulet
SOSherry Owens
Sherry Owens
RNRobert C. Newton
Robert C. Newton
TBTimothy C. Burn
Timothy C. Burn
Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma and to uncover unique molecular features of patients harboring FGFR2 rearrangements. The results highlight the high percentage of patients with cholangiocarcinoma harboring potentially actionable genomic alterations and the diversity in gene partners that rearrange with FGFR2. Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance. Genomic subsets of patients with other potentially actionable FGF/FGFR alterations were also identified. Our study provides a framework for molecularly guided clinical trials and underscores the importance of genomic profiling to enable a deeper understanding of the molecular basis for response and nonresponse to targeted therapy. Significance: We utilized genomic profiling data from FIGHT-202 to gain insights into the genomic landscape of cholangiocarcinoma, to understand the molecular diversity of patients with FGFR2 fusions or rearrangements, and to interrogate the clinicogenomics of patients treated with pemigatinib. Our study highlights the utility of genomic profiling in clinical trials. This article is highlighted in the In This Issue feature, p. 211

1 December 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
RKRichard D. Kim
Richard D. Kim
DSDebashis Sarker
Debashis Sarker
TMTim Meyer
Tim Meyer
TYThomas Yau
Thomas Yau
TMTeresa Macarulla
Teresa Macarulla
YKYoon-Koo Kang
Yoon-Koo Kang
Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as a novel therapeutic target. We evaluated fisogatinib (BLU-554), a highly potent and selective oral FGFR4 inhibitor, in a phase I dose-escalation/dose-expansion study in advanced HCC using FGF19 expression measured by IHC as a biomarker for pathway activation. For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily; the maximum tolerated dose (600 mg once daily) was expanded in 81 patients. Fisogatinib was well tolerated; most adverse events were manageable, grade 1/2 gastrointestinal events, primarily diarrhea, nausea, and vomiting. Across doses, the overall response rate was 17% in FGF19-positive patients [median duration of response: 5.3 months (95% CI, 3.7–not reached)] and 0% in FGF19-negative patients. These results validate FGFR4 as a targetable driver in FGF19-positive advanced HCC. Significance: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC. These results validate the oncogenic driver role of the FGFR4 pathway in HCC and the use of FGF19 as a biomarker for patient selection. See related commentary by Subbiah and Pal, p. 1646. This article is highlighted in the In This Issue feature, p. 1631